Press Release
InnoCare Announces Dosing of First Patient in Phase II Clinical Trial Using Orelabrutinib for the Treatment of ITP
22 Feb, 2022
115
3657
InnoCare and Keymed Jointly Announce Dosing of First Patient in Clinical Trial of CD20xCD3 Bispecific Antibody CM355
18 Jan, 2022
66
3650
InnoCare to Attend Upcoming Investor Conferences to Share Latest Company Development
07 Jan, 2022
117
3643
Orelabrutinib Data Presented at the 63rd Annual Meeting of ASH
13 Dec, 2021
151
3623
InnoCare Announces Inclusion of Orelabrutinib in China National Reimbursement Drug List
03 Dec, 2021
144
3616
InnoCare Announces the Clearance of Clinical Trial of Novel SHP2 Allosteric Inhibitor ICP-189 by U.S. FDA
15 Nov, 2021
100
3599
InnoCare to Attend Upcoming Investor Conferences to Share Latest Company Development
12 Nov, 2021
89
3596
InnoCare to Present Orelabrutinib Data at the Upcoming 63rd Annual Meeting of ASH
08 Nov, 2021
114
3590
InnoCare Announces Approval of Clinical Trial of Novel SHP2 Allosteric Inhibitor ICP-189 in China
19 Oct, 2021
113
3579
BIOGEN AND INNOCARE ANNOUNCE DOSING OF FIRST PATIENT IN PHASE 2 CLINICAL TRIAL OF ORELABRUTINIB FOR THE TREATMENT OF MULTIPLE SCLEROSIS IN CHINA
14 Oct, 2021
103
3612